Events - Spark Newswire

4 minute read

Seres Therapeutics Presents Research From Early-Stage Microbiome Therapeutic Oncology Programs At ASCO 2021 Meeting

Today, 3:30 AM

Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, today announced data from their collaboration with the University of Cologne (Köln, Germany) demonstrating that decreased

MCRB

3 minute read

ADC Therapeutics Presents Updated Clinical Data At 2021 ASCO Meeting

By Benzinga Newsdesk

Today, 3:30 AM

ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced updated

ADCT

2 minute read

EXCLUSIVE: Trulieve CEO On Harvest Deal, Shifting Cannabis Industry Focus, Social Equity

By Andrew Ward

Today, 3:30 AM

Trulieve Cannabis Corporation (OTCQX: TCNNF) CEO Kim Rivers opened day two of the Benzinga Cannabis Capital Conference Friday with Cheddar Reporter Chloe Aiello.

HRVSF

3 minute read

Merus Presents Clinical Data On Zenocutuzumab In NRG1-fusion (NRG1+) Cancers At 2021 ASCO Meeting

By Benzinga Newsdesk

Today, 3:30 AM

Merus N.V. (NASDAQ:MRUS) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and

MRUS

5 minute read

Alkermes Says Presents New Data On Nemvaleukin Alfa At 2021 ASCO Meeting

By Benzinga Newsdesk

Today, 3:30 AM

Alkermes plc (NASDAQ:ALKS) today announced new data from its ARTISTRY clinical development program for nemvaleukin alfa (nemvaleukin), Alkermes' novel, investigational engineered interleukin-2 (IL-2)

ALKS

1 minute read

Events
News

Celldex Presents Preliminary Data from Ongoing CDX-527 Phase 1 Dose Escalation Trial at the 2021 ASCO Annual Meeting

By Benzinga Newsdesk

Today, 3:30 AM

Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced preliminary data from the Company’s Phase 1 dose escalation study of PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies. These

CLDX

2 minute read

Events
News

Jounce Therapeutics Presents Trial in Progress Posters on the INNATE and SELECT Clinical Trials at the 2021 American Society of Clinical Oncology Virtual Annual Meeting

By Benzinga Newsdesk

Today, 3:30 AM

- INNATE trial to include proof-of-concept expansion cohorts in lung, renal, head and neck, triple negative breast, cutaneous squamous cell, and ovarian cancers and soft tissue sarcomas - - SELECT TISvopra positivity

JNCE

3 minute read

Agenus Says Co’s Presentations At ASCO 2021 ‘Demonstrate Differentiated Activity of Balstilimab and Provide Clinical Update on AGEN2373’

By Benzinga Newsdesk

Today, 3:30 AM

Agenus (NASDAQ:AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections,

AGEN

1 minute read

Events
News

Deciphera Pharmaceuticals Presents Data from QINLOCK® and Rebastinib Programs at the 2021 American Society of Clinical Oncology Annual Meeting

By Benzinga Newsdesk

Today, 3:30 AM

– Exploratory Analysis of the INVICTUS Phase 3 Study Showed QINLOCK Dose Escalation After Disease Progression Provided Substantial Clinical Benefit in Advanced GIST – – Rebastinib in Combination with

DCPH

6 minute read

BeiGene Presents Clinical Data From 2 Phase 2 Trials Of Pamiparib At 2021 ASCO Meeting

By Benzinga Newsdesk

Today, 3:30 AM

Pamiparib, a potent and selective PARP1 and PARP2 inhibitor, demonstrated meaningful and durable efficacy in patients with advanced HER2-negative breast cancer Pamiparib showed numerically higher progression-free

BGNE